Prevention and Treatment of Hepatocellular Carcinoma Using miRNAs

Zahra Farzaneh ¹, Maryam Farzaneh ^2,3 *

Cited by CrossRef: 4

1- Zhang B, Zhu B, Yu J, Liu H, Zhou Y, Sun G, Ma Y, Luan Y, Chen M. A combined model of six serum microRNAs as diagnostic markers for hepatocellular carcinoma. Clinica Chimica Acta. 2025;565:119977 [Crossref]

2- Azizidoost S, Nasrolahi A, Sheykhi-Sabzehpoush M, Akiash N, Assareh A, Anbiyaee O, Antosik P, Dzięgiel P, Farzaneh M, Kempisty B. Potential roles of endothelial cells-related non-coding RNAs in cardiovascular diseases. Pathology - Research and Practice. 2023;242:154330 [Crossref]

3- Zhou G, Qin X, Chen X, Dai M, Liu L, Liu Y. Study on the Expression of GAB/GBAP1 Gene in Hepatocellular Carcinoma and Its Functional Mechanism of Interaction with miRNAs. j biomed nanotechnol. 2024;20(8):1372 [Crossref]

4- Farzaneh M, Anbiyaee O, Azizidoost S, Nasrolahi A, Ghaedrahmati F, Kempisty B, Mozdziak P, Khoshnam S, Najafi S. The Mechanisms of Long Non-coding RNA-XIST in Ischemic Stroke: Insights into Functional Roles and Therapeutic Potential. Mol Neurobiol. 2024;61(5):2745 [Crossref]

5- Shah D, Dave B, Patel P, Chorawala M, Patel V, Shah P, Patel M. Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities. Med Oncol. 2023;40(2) [Crossref]

Submit Your Paper Notification Instructions for Authors Aims and Scope Editorial policies Editorial Board AIM old site Archive

About Us

A Monthly Peer-Reviewed Medical Journal Published by the Academy of Medical Sciences of the I.R. Iran; Indexed in PubMed/MEDLINE, ISI Web of Science, EMBASE, SCOPUS, CINHAL, PASCAL, CSA, SID, ISSN: Print 1029-2977, Online 1735-3947.The impact factor of Archives of Iranian Medicine according to Journal Citation Reports® (JCR®) 2016 is 1.20.